Climb Bio Inc (CLYM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Climb Bio Inc (CLYM) has a cash flow conversion efficiency ratio of -0.097x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-15.63 Million) by net assets ($160.47 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Climb Bio Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Climb Bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read CLYM liabilities breakdown for a breakdown of total debt and financial obligations.
Climb Bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Climb Bio Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
TaiMed Biologics
TWO:4147
|
0.029x |
|
Angel Oak Financial Strategies Income Term Trust
NYSE:FINS
|
0.033x |
|
Yunnan luoping Zinc & Electricity Co Ltd
SHE:002114
|
0.044x |
|
Beijing Hanbang Technology Corp
SHE:300449
|
-0.118x |
|
Cable One Inc
NYSE:CABO
|
0.102x |
|
Meihua International Medical Technologies Co Ltd
NASDAQ:MHUA
|
-0.120x |
|
J.Kumar Infraprojects Limited
NSE:JKIL
|
0.129x |
|
Xinjiang Talimu Agriculture Development Co Ltd
SHG:600359
|
-0.010x |
Annual Cash Flow Conversion Efficiency for Climb Bio Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Climb Bio Inc from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Climb Bio Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $160.47 Million | $-54.36 Million | -0.339x | -361.18% |
| 2024-12-31 | $211.88 Million | $-15.56 Million | -0.073x | +61.63% |
| 2023-12-31 | $107.60 Million | $-20.60 Million | -0.191x | +34.06% |
| 2022-12-31 | $128.72 Million | $-37.37 Million | -0.290x | -34.57% |
| 2021-12-31 | $167.20 Million | $-36.07 Million | -0.216x | +67.00% |
| 2020-12-31 | $21.57 Million | $-14.10 Million | -0.654x | -169.03% |
| 2019-12-31 | $20.61 Million | $-5.01 Million | -0.243x | -- |
About Climb Bio Inc
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies for immune-mediated diseases. The company develops budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug IV for the treatment of primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus. In addition, the co… Read more